- Email: [email protected]
CLINICAL OUTCOMES AFTER IMPLANTATION OF ABSORB BVS IN A REAL WORLD SETTING, WITH PRE- AND POST-DILATATION, GUIDED BY INTRAVASCULAR ULTRASOUND & OPTICAL COHERENCE TOMOGRAPHY
1125 JACC March 21, 2017 Volume 69, Issue 11
Interventional Cardiology CLINICAL OUTCOMES AFTER IMPLANTATION OF ABSORB BVS IN A REAL WORLD SETTING, WITH PRE- AND POST-DILATATION, GUIDED BY INTRAVASCULAR ULTRASOUND & OPTICAL COHERENCE TOMOGRAPHY Poster Contributions Poster Hall, Hall C Friday, March 17, 2017, 3:45 p.m.-4:30 p.m. Session Title: Coronary Intervention in Interventional Cardiology: Advanced Device Use Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices Presentation Number: 1155-166 Authors: Costantino R. Costantini, Sergio Tarbine, Costantino O. Costantini, Marcelo Freitas, Daniel A. Zanuttini, Marcos Denk, Hospital Cardiologico Costantini, Curitiba, Brazil
Background: The safety & performance of the Absorb Bioresorbable Vascular Scaffold has been previously demonstrated with clinical data. However, these trials included patients with simple lesions. Aiming to evaluate clinical outcomes, we analyzed the treatment of real world patients from a single center.
Methods: between 11/2014 & 09/2016, consecutive unselected pts. were treated with one or more Absorb BVS. Pre dilatation before stent deployment, & post dilatation, Intravascular Ultrasound (IVUS) & Optical Coherence Tomography (OCT) were used in 99% of cases.
Results: 91 pts (89% male, mean age 57.97±10.09 yo) were included in this analysis. Diabetes was present in 32% & multivessel ds. in 52%. 32% had stable angina. A total of 150 lesions were treated (LAD 61%), being B/C class in 75%. The median SYNTAX score was 13.24±8.78 The total number of Absorb BVS implanted was 176, with an average of 1.72 per patient. Further intervention following imaging & optimization with balloon was necessary in 18% of cases, regarding IVUS/OCT. With 100% procedure success rate, definite/probable scaffold thrombosis occurred in 0%. Target lesion failure (cardiac death, target vessel MI, or clinically driven TLR) occurred in 2.2% & TVR, caused by disease progression, in 3,3% at 7 months mean follow up.
Conclusions: The analysis of this cohort, is showing no thrombosis & low MACE rate so far, in a real world setting. Predilatation, the use of IVUS/OCT in all cases, & final balloon optimization might have impact on clinical outcomes. Long term 9 months angiography, with IVUS & OCT will be performed
Interventional Cardiology CLINICAL OUTCOMES AFTER IMPLANTATION OF ABSORB BVS IN A REAL WORLD SETTING, WITH PRE- AND POST-DILATATION, GUIDED BY INTRAVASCULAR ULTRASOUND & OPTICAL COHERENCE TOMOGRAPHY Poster Contributions Poster Hall, Hall C Friday, March 17, 2017, 3:45 p.m.-4:30 p.m. Session Title: Coronary Intervention in Interventional Cardiology: Advanced Device Use Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices Presentation Number: 1155-166 Authors: Costantino R. Costantini, Sergio Tarbine, Costantino O. Costantini, Marcelo Freitas, Daniel A. Zanuttini, Marcos Denk, Hospital Cardiologico Costantini, Curitiba, Brazil
Background: The safety & performance of the Absorb Bioresorbable Vascular Scaffold has been previously demonstrated with clinical data. However, these trials included patients with simple lesions. Aiming to evaluate clinical outcomes, we analyzed the treatment of real world patients from a single center.
Methods: between 11/2014 & 09/2016, consecutive unselected pts. were treated with one or more Absorb BVS. Pre dilatation before stent deployment, & post dilatation, Intravascular Ultrasound (IVUS) & Optical Coherence Tomography (OCT) were used in 99% of cases.
Results: 91 pts (89% male, mean age 57.97±10.09 yo) were included in this analysis. Diabetes was present in 32% & multivessel ds. in 52%. 32% had stable angina. A total of 150 lesions were treated (LAD 61%), being B/C class in 75%. The median SYNTAX score was 13.24±8.78 The total number of Absorb BVS implanted was 176, with an average of 1.72 per patient. Further intervention following imaging & optimization with balloon was necessary in 18% of cases, regarding IVUS/OCT. With 100% procedure success rate, definite/probable scaffold thrombosis occurred in 0%. Target lesion failure (cardiac death, target vessel MI, or clinically driven TLR) occurred in 2.2% & TVR, caused by disease progression, in 3,3% at 7 months mean follow up.
Conclusions: The analysis of this cohort, is showing no thrombosis & low MACE rate so far, in a real world setting. Predilatation, the use of IVUS/OCT in all cases, & final balloon optimization might have impact on clinical outcomes. Long term 9 months angiography, with IVUS & OCT will be performed